Scarica l'app Stockscreener
0.9851
1.49%
-0.0149
Dopo l'orario di chiusura:
1.00
0.0149
+1.51%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.00
Aprire:
$1
Volume 24 ore:
54,214
Relative Volume:
0.10
Capitalizzazione di mercato:
$11.44M
Reddito:
-
Utile/perdita netta:
$-10.93M
Rapporto P/E:
-0.6851
EPS:
-1.4378
Flusso di cassa netto:
$-10.72M
1 W Prestazione:
-2.47%
1M Prestazione:
-12.82%
6M Prestazione:
-23.04%
1 anno Prestazione:
-58.78%
Intervallo 1D:
$0.9804
$1.02
Intervallo di 1 settimana:
$0.9804
$1.0669
Portata 52W:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
0.9851 | 11.73M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
A director buys 10,000 shares of Phio Pharmaceuticals (PHIO) at $1.03 and $1.04 per share. - Stock Titan
Phio Pharmaceuticals CEO Robert J. Bitterman Awarded 400,000 Restricted Stock Units - kalkinemedia.com
Phio Pharmaceuticals Director Ronald Todd Plott Granted 17,000 Restricted Stock Units - kalkinemedia.com
Phio Pharmaceuticals CFO Lisa Cabott Carson Granted 108,000 Restricted Stock Units - kalkinemedia.com
A director’s grant at Phio Pharmaceuticals (PHIO) covers 17,000 shares that vest in a year. - Stock Titan
A CEO's stock award will vest after a year at Phio Pharmaceuticals (PHIO). - Stock Titan
Phio Pharmaceuticals Stockholders Endorse 2026 Annual Meeting Proposals Including Director Elections and Incentive Plan Expansion - kalkinemedia.com
Phio Pharmaceuticals Expands Equity Incentive Pool at Meeting - TipRanks
Director Patricia Bradford Buys 6,500 Shares of Phio Pharmaceuti - GuruFocus
At $1.0127 a share, a Phio Pharmaceuticals (PHIO) director bought 6,500 shares. - Stock Titan
Phio Pharmaceuticals to Present Clinical Development Update - openPR.com
Phio Pharmaceuticals (PHIO) Chairman, President & CEO Robert Bit - GuruFocus
Phio Pharmaceuticals to Present Clinical Development Update & Upc - natlawreview.com
A CEO buys Phio Pharmaceuticals (PHIO) shares at $1.0289 each; reported direct holdings total 364,871 shares. - Stock Titan
Phio Pharmaceuticals Corp. (PHIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
A potential skin cancer treatment completed a clinical study. Phio will discuss next steps Sept. 30. - Stock Titan
Live Phio Pharmaceuticals Corp. (PHIO) Technical Analysis - Traders Union
Phio Pharmaceuticals Corp. Stock Price Prediction: Today, Tomorrow, Next Week (PHIO) - Traders Union
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - kalkine.com.au
Phio Pharmaceuticals (NASDAQ: PHIO) Director Patricia A. Bradford Acquires 12,000 Shares at $1.03 Each - Kalkine Media
Phio Pharmaceuticals (PHIO) director buys shares with no 10b5-1 plan reported - Stock Titan
Phio Pharmaceuticals (PHIO) CEO has 68,550 shares withheld for taxes - Stock Titan
Phio Announces Key Development Milestone for PH-762 with FDA - openPR.com
Phio Pharmaceuticals (PHIO) CFO’s 12,888-share tax move involves no market sale - Stock Titan
Phio Announces PH-762 Milestone with FDA Submission Supporting Clinical Development in Cutaneous Squamous Cell Carcinoma - EIN News
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Nigeria
King of Prussia's Phio Pharmaceuticals Submits FDA Briefing Package to Advance Its Skin Cancer Gene-Silencing Therapy - BioBuzz
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial - TipRanks
Phio Pharmaceuticals submits FDA briefing for PH-762 study By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals submits FDA briefing for PH-762 study - Investing.com
Plans for a skin-cancer study reach the FDA after Phio completes an early trial - Stock Titan
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma - Yahoo Finance
Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang
A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan
PHIO Q2 2026 Earnings: EPS of -$0.36 Slightly Beats Consensus as Company Remains Pre-RevenueCEO Earnings Statement - dars.gov.et
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHIO Should I Buy - Intellectia AI
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - stocktitan.net
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phio Pharmaceuticals Corp Azioni (PHIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Plott Ronald Todd | Director |
Sep 28 '26 |
Buy |
1.03 |
5,000 |
5,150 |
37,000 |
| BRADFORD PATRICIA A | Director |
Sep 24 '26 |
Buy |
1.01 |
6,500 |
6,583 |
64,151 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Sep 22 '26 |
Buy |
1.03 |
2,000 |
2,058 |
364,871 |
| BRADFORD PATRICIA A | Director |
Sep 15 '26 |
Buy |
1.03 |
12,000 |
12,360 |
57,651 |
| Plott Ronald Todd | Director |
Aug 19 '26 |
Buy |
1.14 |
15,000 |
17,100 |
15,000 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Aug 18 '26 |
Buy |
1.06 |
10,000 |
10,600 |
431,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Jun 26 '26 |
Buy |
0.99 |
10,000 |
9,900 |
421,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 31 '25 |
Buy |
1.03 |
5,000 |
5,150 |
291,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):